Clinical and histopathological correlations of immunoreactivity to Chlamydia trachomatis and to epitopes of the C.trachomatis 60 kDa heat shock protein (hsp60) among women with ectopic pregnancy were evaluated in a casecontrol study. Serological responses to 13 synthetic peptides corresponding to major epitopes of the chlamydial hsp60 were determined in 67 women treated for ectopic pregnancy and 45 women with uncomplicated pregnancy in utero. Plasma cell salpingitis was detected in 29 (43.3%) of the ectopic patients. Its presence correlated with antibodies to two hsp60 epitopes, encompassing amino acids 260-271 and 411-422 (P ϭ 0.02). Antibodies to these two epitopes, along with five other epitopes, also correlated with peritubal adhesion formation in ectopic pregnant patients (P Ͻ 0.01). Antibodies to epitopes 260-271 and 188-199 also correlated with a history of pelvic inflammatory disease (PID; P ϭ 0.05). Patients with ectopic pregnancy were also more likely than their intrauterine pregnant controls to have present anti-chlamydial immunoglobulin G (P Ͻ 0.005). Women positive for both C.trachomatis and hsp60 epitope antibodies had an increased prevalence over controls of salpingitis, pelvic adhesions or history of PID (P Ͻ 0.05). In contrast, patients who were positive for only C.trachomatis antibodies or only hsp60 epitope antibodies did not differ from antibody-negative patients in each of these categories.
Introduction
Ectopic pregnancy remains a significant cause of pregnancyrelated maternal morbidity and first trimester maternal mortality (Centers for Disease Control, 1993) . Its increasing incidence in many parts of the world has resulted in growing interest in its aetiology. Several case-control studies and cohort analyses have concluded that a substantial proportion of ectopic pregnancies are caused by late consequences of Chlamydia tracho-
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© European Society for Human Reproduction and Embryology matis-associated salpingitis (Beral, 1975; Westrom et al., 1981; Svensson et al., 1985; Brunham et al., 1986 Brunham et al., , 1992 . Despite the strong epidemiological, histological and serological correlations between chlamydial upper genital tract infection and subsequent ectopic pregnancy or tubal infertility, the pathogenic mechanism leading to tubal damage remains to be determined.
In an experimental monkey model repeated C.trachomatis inoculations, but not a single inoculation, resulted in extensive tubal damage and occlusion (Patton et al., 1987) . This suggested the involvement of the host's immune response in tubal pathogenesis. Subsequent studies in both monkeys (Patton et al., 1994) and guinea pigs (Morrison et al., 1989a) demonstrated that subsequent exposure of the animals with a prior C.trachomatis infection to a single chlamydial antigen, the 60 kDa heat shock protein (HSP60), led to a delayed hypersensitivity response and marked localized inflammation.
The chlamydial hsp60 has been identified as a homologue of the GroEL family of heat shock proteins that stimulate immunodominant antibodies in humans (Morrison et al., 1989b) . The amino acid sequences of hsp60 have been highly conserved throughout evolution, and a cross-reactive immune response between the chlamydial and human homologues has been implicated in chlamydial pathology. Clinical observations linking a serological response or cell-mediated immune response to the chlamydial hsp60 with tubal pathology has been reported by different groups (Wagar et al., 1990; Brunham et al., 1992; Toye et al., 1993; Witkin et al., 1994a; Arno et al., 1995) .
Using 533 overlapping 12mer synthetic peptides covering the entire sequence of the C.trachomatis hsp60, antibody responses to specific epitopes were identified in sera from immunized rabbits and from women with C.trachomatisassociated ectopic pregnancy (Yi et al., 1993) . Overall, 13 major hsp60 epitopes reacted with antibodies in human sera. Seven of these antibodies were also reactive with homologous peptide sequences in human hsp60.
Previous observations regarding ectopic pregnancy, tubal pathology and immunoreactivity to chlamydial hsp60 have been limited, however, by relatively small sample sizes. In addition, hsp60 antibody status was examined only in those patients positive for anti-C.trachomatis antibodies, and responses to different epitopes of the chlamydial hsp60 were not investigated with regard to clinical and histological correlations of tubal pathology. We therefore further analysed the role of hsp60-mediated immune mechanisms in the aetiology of tubal damage leading to ectopic pregnancy. Serological responses to the 13 immunodominant chlamydial hsp60 epitopes were evaluated in (i) women with ectopic and intrauterine pregnancies, (ii) within the ectopic group between women with and without histological salpingitis, pelvic adhesions and a history of pelvic inflammatory disease, and (iii) in women both positive and negative for anti-chlamydial immunoglobulin (Ig) G.
Materials and methods

Study population
A case-control study was undertaken among patients treated for ectopic pregnancy between 1989 and 1993. Sera from consecutive patients were drawn at the time of operation or within the subsequent 24 h. In all cases, the diagnosis of ectopic pregnancy was confirmed by a histological evaluation of the removed Fallopian tube specimen. This study was approved by the ethics committee for human research at Semmelweis University Medical School, Budapest, Hungary.
All women undergoing medical treatment for ectopic pregnancy were considered possible candidates for enrolment. Women using an intrauterine contraceptive device (IUD) at the time of conception were excluded from the study. The control group consisted of sera from women with uncomplicated intrauterine pregnancies who had completed up to week 16 of gestation. Enrolment in the control group was performed randomly by a senior midwife responsible for the pregnancy care clinic.
A total of 67 women with a tubal ectopic gestation who had an available Fallopian tube specimen for histological evaluation and fulfilled the inclusion criteria formed the study group. The control group consisted of 45 women with an uncomplicated intrauterine pregnancy who delivered at term.
Collection of data
After informed consent was obtained, both cases and controls were interviewed using a questionnaire for age, socio-demographic characteristics and medical and obstetric histories. The removed Fallopian tube biopsy specimen was examined for microscopic signs of chronic infection, with special regard to plasma cell infiltration of the subepithelial layer. A diagnosis of plasma cell salpingitis was made for cases when at least 10 plasma cells per ϫ400 microscopic field were visible. Macroscopic evidence of previous pelvic infection (adhesions) was recorded at the time of the operation.
Serological studies
All sera were aliquoted and kept at -20°C until evaluated for anti-chlamydial IgG by a commercially available diagnostic kit (SeroELISA; Savyon Diagnostics, Beer-Sheva, Israel). In this assay, IgG antibodies to C.trachomatis were determined using the L2 serovar antigen. The tests were performed according to the instructions of the manufacturer. A positive result was equivalent to an estimated titre of anti-chlamydial IgG Ͼ1:256.
Serological responses to the linear B cell epitopes of the 60 kDa C.trachomatis hsp60 were determined by an enzyme-linked immunosorbent assay using biotinylated synthetic peptides (Chiron Mimotopes, Clayton, Australia) representing 13 different 12mer epitopes of the chlamydial hsp60. The peptides were reconstituted in 0.2 ml 100% dimethyl sulphoxide, diluted 1:100 in phosphatebuffered saline (PBS) containing 0.1% bovine serum albumin (BSA) and 0.1% sodium azide, and stored in aliquots at -80°C. A 92-well microtitre plate (Nunc ImmunoPlate MaxiSorb) was first coated with streptavidin diluted in purified water overnight. After washing the plates with PBS-Tween 20, 100 µl of 100 µg/ml peptide solutions were added to corresponding wells of the plate and placed on a shaker for 1 h at room temperature. After repeated washings, 100 µl of the patients' sera, diluted 1:50 in 2% BSA/PBS containing 0.1% sodium azide, were added to the wells and incubated for 2 h in a water bath at 37°C. Bound antibodies were detected after the reaction for 1 h at room temperature with 100 µl anti-human IgG conjugate solution (comprising a saturating level of horseradish peroxidaselabelled anti-human antibody at 1:200 dilution in 2% BSA/PBS). After washing the wells with PBS, 100 µl of a peroxidase substrate (ABTS; Boehringer Mannheim, Germany) were added to each well and incubated at room temperature for 30 min. The absorbance of the converted substrate solutions was determined using a microtitre plate reader in the dual wavelength mode at 405 nm against a reference wavelength of 492 nm. On each microtitre plate, sera from healthy women negative for anti-chlamydial IgG and with no history of a previous chlamydial infection were assayed as controls. A sample was considered positive for antibodies to a specific epitope if the absorbance exceeded the mean ϩ 2SD of the absorbance recorded for the negative controls for that epitope. The mean absorbance values of the control sera for the 13 epitopes were between 0.220 and 0.279 (SD 0.022-0.030). Therefore the lower limit of a sample being considered positive for antibodies to any epitope was defined as an absorbance of 0.340.
Statistical analyses
For statistical analysis, the χ 2 and Fisher's exact tests were used for comparing discrete variables. Statistical comparisons for means were performed using Student's t-test. A P value Ͻ0.05 was considered to be statistically significant.
Results
Demographic and historical variables
The demographic and historical comparisons between ectopic and intrauterine pregnancy patients are shown in Table I . Both groups were similar with regard to age, gravidity and education. However, the women with ectopic pregnancies were more likely to be unmarried (P Ͻ 0.04), have a prior history of ectopic pregnancy (P Ͻ 0.04) or to have had at least one prior episode of medical treatment for pelvic inflammatory disease (PID; P Ͻ 0.05). Ectopic pregnancy patients also had a higher prevalence of exposure to C.trachomatis (52.2%), as shown by the presence of anti-chlamydial IgG, than did controls (26.7%) (P Ͻ 0.005).
Heat shock protein epitope antibodies in ectopic and intrauterine pregnancies
The presence of antibodies to each of the synthetic peptide hsp60 epitopes in women with ectopic or intrauterine pregnancies is shown in Table II . Between 9.0 and 38.8% of ectopic patients, as opposed to 0.0-6.7% of controls, were positive for any of the hsp60 epitopes. For 11 of the 13 epitopes the prevalence of antibody was significantly greater in the ectopic patients. Antibodies to a single epitope, corresponding to amino acids 260-271, were absolutely specific for the women with ectopic pregnancies, being present in 35.8% of these women as opposed to none of the intrauterine pregnant controls (P Ͻ 0.0001).
Plasma cell salpingitis and heat shock protein epitope antibodies
A histological diagnosis of plasma cell salpingitis was made in 29 (43.3%) of the women with ectopic pregnancies. The relationship between histological salpingitis and antibodies to the hsp60 epitopes is shown in Table III . Antibodies to two of the epitopes, corresponding to amino acids 260-271 and 411-422, were observed in 15 (51.7%) of the women with salpingitis but in only nine (23.7%) of the women without this diagnosis (P ϭ 0.02). There was no association between immunity to any of the other epitopes and plasma cell salpingitis.
Peritubal pelvic adhesions and antibodies to heat shock protein epitopes
Peritubal pelvic adhesions were visualized in 26 (38.8%) of the ectopic pregnancy patients. The relationship between this finding and antibodies to the hsp60 epitopes is shown in Table  IV . Once again, antibodies to epitopes 260-271 and 411-422 were associated with tubal pathology, being present in 57.7 and 53.8% of women with, and in 21.9 and 24.4% of women without, adhesions (P Ͻ 0.01). Antibodies to five other hsp60 epitopes were also associated with peritubal adhesions. 
Previous pelvic inflammatory disease and antibodies to heat shock protein epitopes
A prior history of PID was reported by 26 (38.8%) of the patients. Antibodies to only two of the hsp60 epitopes, amino acids 188-199 and 260-271, were more prevalent in women with a prior diagnosed PID (P ϭ 0.05; Table V) .
Any criteria of pelvic infection and antibodies to heat shock protein epitopes
A total of 42 (62.7%) of the ectopic pregnancy patients was positive for at least one indicator of a pelvic infection: histological salpingitis, pelvic adhesions and/or a history of PID. The relationship between any of these findings and antibodies to the heat shock protein epitopes is shown in Table  VI . Antibodies to seven of these epitopes, spanning amino acids 188-461, were most prevalent in women with prior pelvic infection. Tubal pathology and antibodies to C.trachomatis and/or heat shock protein peptide epitopes Among the 35 ectopic pregnancy patients with antibodies to C.trachomatis surface components, 27 (77.1%) were also positive for antibodies to at least one of the hsp60 epitopes. Similarly, among the 36 women with hsp60 peptide antibodies, 27 (75.0%) were positive for C.trachomatis antibodies. The relationship between antibodies to C.trachomatis and/or antibodies to the hsp60 epitopes and tubal pathology is shown in Table VII . Women with antibodies to only C.trachomatis or the hsp60 epitopes did not differ from antibody-negative ectopic patients in terms of the prevalence of prior ectopic pregnancy or PID, histological salpingitis or pelvic adhesions. In contrast, women who were positive for both antibodies had a higher prevalence than the antibody-negative patients in terms of histological salpingitis (P ϭ 0.002), pelvic adhesions (P ϭ 0.0002) and past history of PID (P ϭ 0.01).
No antibodies to C.trachomatis or hsp60 epitopes were identified in 23 out of 67 (34.3%) of the ectopic pregnancy patients. In addition, nine of the 39 (25%) patients with hsp60 antibodies were negative for anti-chlamydial IgG.
Discussion
In our study only those women with hsp60 antibodies who were also seropositive for exposure to C.trachomatis had an increased prevalence of histological salpingitis, pelvic adhesions and a past history of PID, compared with ectopic patients who were negative for both hsp60 and chlamydial antibodies. This strongly suggests that a prior or prolonged C.trachomatis infection may be necessary for the induction of hsp60-related tubal immunopathology. Immune sensitization of the host to specific regions of the chlamydial hsp60 might be responsible for initiating a delayed hypersensitivity reaction within the Fallopian tubes, resulting in tubal distortion or peritubal pelvic adhesions. Furthermore, the proportion of patients with antibodies to one or more antigenic sites within the chlamydial hsp60 was significantly higher among patients with ectopic pregnancy compared with women with an uncomplicated intrauterine pregnancy. Given the large sample size in this study, these data strongly support the association between C.trachomatis and ectopic gestation, and further implicate immunoreactivity to the chlamydial hsp60 in the aetiology of tubal disease and/ or ectopic pregnancy. Additional studies, now in progress, to demonstrate hsp60 and/or anti-hsp60 antibodies in tubal tissue, should further improve our understanding of the aetiology of tubal damage leading to ectopic implantation.
Chlamydia trachomatis is certainly not the only cause of ectopic pregnancy, as demonstrated by the absence of immunity to this organism in 34.3% of ectopic pregnancies. In addition, the presence of antibodies reactive with chlamydial hsp60 epitopes in the absence of antibodies to chlamydial structural components in other patients suggests that hsp60 antibodies might also be elicited by other micro-organisms. The control group with term pregnancies were obviously not examined surgically for pelvic adhesions or evidence of salpingitis. Therefore we are unable to comment in this study as to whether the detection of antibodies to hsp60 and/or C.trachomatis in some members of this group might also be associated with these pathological findings.
In an attempt to localize immunogenic regions of the hsp60 molecule associated with tubal disease, serological responses of patients to amino-truncated fragments of recombinant chlamydial hsp60 have been examined (Arno et al., 1995) . Patients' sera were shown to react predominantly with the region of the hsp60 comprising amino acids 201-300. Previously we have demonstrated that the presence of secretory cervical IgA antibodies reactive with chlamydial hsp60 in women undergoing in-vitro fertilization correlated with implantation failure after embryo transfer (Witkin et al., 1994b) . Furthermore, a single immunodominant chlamydial hsp60 epitope, comprising amino acids 260-271, was identified by these cervical IgA antibodies (Witkin et al., 1996) . This observation parallels the findings in our study where immunity to this same epitope was associated with ectopic pregnancy and the presence, among ectopic women, of plasma cell salpingitis and peritubal adhesions.
The association of only two chlamydial hsp60 epitopes, spanning amino acids 260-271 and 411-422, with both plasma cell salpingitis and peritubal pelvic adhesions suggests that in at least some patients an immune response to these epitopes might be involved in the aetiology of tubal pathology. In addition, the restriction of antibodies to peptide 260-271 to ectopic pregnant women, as opposed to intrauterine pregnant women, further supports this hypothesis. Interestingly, antibodies to both of the above epitopes of chlamydial hsp60 have also been shown to react with the corresponding regions in human HSP60 (Yi et al., 1993) . Therefore, women sensitized to these regions of chlamydial hsp60 would also be expected to respond immunologically to their own HSP60. Endogenous HSP60 production is induced by pro-inflammatory mediators. Therefore once a woman becomes sensitized to conserved HSP60 epitopes any inducer of tubal inflammation, whether it be C.trachomatis, another micro-organism or an extrauterine pregnancy, would induce self-HSP60 expression and reactivate an hsp60-sensitized lymphocyte response. This may create complications for those situations where self-HSP60 expression is a component of a normal physiological mechanism. Cell surface HSP60 expression has been reported for activated mononuclear phagocytic cells (Wand-Wurttenberger et al., 1991) as well as for T lymphocytes bearing the γ-δ form of the antigen receptor (Jarjour et al., 1990) , endothelial cells (Xu et al., 1994) and uterine decidual cells (Mincheva-Nilsson et al., 1994) . Immunity to hsp60, therefore, might subvert homeostatic mechanisms into pro-inflammatory pathological events with adverse clinical consequences.
